Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.
Natalie Schwehr Mac ArthurKaren M KuntzEva A EnnsNathan D ShippeeElaine KingwellHelen TremlettAdam F CarpenterMary Butlernull nullPublished in: Drugs & aging (2020)
The benefits of DMDs may not be substantial among older adults with relapsing-onset MS. Direct clinical evidence remains limited and the decision of whether to discontinue a DMD should also take into account patient preferences. It is important to gain a better understanding of how age-related changes in the trajectory of relapsing-onset MS affect treatment effectiveness among older adults.